Aldeyra Therapeutics, Inc.

Todd Brady

Scott Young

William Alvin Kinney

Kenneth Jason Mandell

Susan Macdonald

Stephen Gitu Machatha

David J Clark

Adam Brockman

The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Deuterated compounds and uses thereof

Toxic aldehyde related diseases and treatment

The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseases, organ diseases, viral infections, and sequelae and associated conditions such as acute respiratory distress syndrome.

Pharmaceutical formulations and uses thereof

The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.

Formulations for treatment of dry eye disease

The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent.

Combination treatment of ocular inflammatory disorders and diseases

The present disclosure provides methods of treating eye allergies and allergic conjunctivitis with cyclodextrin. Ophthalmic compositions of cyclodextrin for topical administration are also provided.

Growing community of inventors

Carlisle, MA, United States of America

Todd Brady